A single-institution chart review of breast cancer patients treated with adjuvant chemotherapy
Notice bibliographique
Résumé
ABSt RACt Rationale: Many of the immediate effects of chemotherapy are widely known, but the late effects postchemotherapy have not been extensively described. The purpose of this study was to determine the statistical occurrence of postchemotherapy arthralgia (PCA) in breast cancer patients in a single institution. The study further attempted to determine if certain chemotherapy regimes, comorbidities or menopausal status correlate with PCA symptoms. Methods: This retrospective chart review included all patients from the Dr. H. Bliss Murphy Cancer Centre with Stage I, II or III breast cancer who received adjuvant chemotherapy during the 2005 calendar year. Information collected included the incidence of reported PCA and correlating factors. Results: A total of 56 charts were eligible for the study, with 51 satisfying the inclusion criteria. Of the eligible charts, 18 (35.3%) reported PCA and 33 (64.7%) did not report PCA. Of the charts reporting PCA, 5 cases (27.8%) were recorded at ≤ 8 weeks postchemotherapy, and 10 (55.5%) between 8 weeks and 16 weeks, inclusive. The remaining 3 charts (16.7%) reported PCA at ≥ 16 weeks. Within the PCA group, 5 patients (27.8%) were treated with fluorouracil + epirubicin + cyclophosphamide (FEC100) for a total of 6 cycles. Five patients (27.8%) were treated with 3 cycles of FEC100 plus 3 cycles of docetaxel. Four cases (22.2%) received 6 cycles of docetaxel + doxorubicin + cyclophosphamide (TAC) and 3 (16.7%) were given 4 cycles of doxorubicin + cyclophosphamide (AC). The remaining patient (5.5%) was treated with dose-dense epirubicin + cyclophosphamide (EC) for 6 cycles plus 4 cycles of paclitaxel. Of the 18 patients in the PCA group, 10 (55.5%) were premenopausal and 8 (44.5%) were postmenopausal prior to chemotherapy. Of the 10 premenopausal PCA patients, 6 (60%) were reported as having become postmenopausal following chemotherapy. Eleven patients (61.1%) in the PCA group were estrogen and/or progesterone receptor (ER/PR)-positive. Of these positive patients, 7 (63.6%) were treated with tamoxifen and 4 (36.4%) received an aromatase inhibitor (AI). Seven (38.9%) patients in the PCA group were ER/PR-negative. Conclusions: Our findings have highlighted that PCA is a common, unpleasant postchemotherapy event for a large proportion of breast cancer patients. It would be beneficial for physicians to inquire about symptoms of PCA and document the details in the patient chart. Furthermore, prospective studies should include specific questions such as character, onset, severity and treatment to help define the typical pattern of PCA. Such information could be used to diagnose this side effect and potentially help differentiate between PCA and onset of metastatic disease. OriginAl res eArch Canadian clinical investigations
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,005 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,003 | 0,003 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,001 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».